**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt and/or hydrate thereof:




(I)

wherein R is $C_{1-4}$ alkyl or $C_{1-4}$ haloalkyl, which comprises reaction of a compound of formula (II):




(II)

wherein X is a leaving group; with a compound of formula (III):




(III)

wherein R is as defined for formula (I), or a salt thereof;

in the presence of a base and an aqueous solvent, wherein the solvent is water; and optionally forming a pharmaceutically acceptable salt and/or hydrate thereof.

2-11. (Canceled)

12. (Previously Presented) The process according to claim 1 wherein 10 volumes of solvent based on the compound of formula (II) are used.

13. (Previously Presented) The process according to claim 1 wherein between 1.01 and 1.08 mole equivalents of the compound of formula (III) based on the compound of formula (II) are used.

14. (Previously Presented) The process according to claim 1 performed at a temperature between ambient and about 60°C.

15. (Previously Presented) The process according to claim 1 wherein the base is triethylamine, diisopropylamine, pyridine, N,N-dimethylaniline, N,N-dimethylaminopyridine, 1 ,8-diazabicyclo[5.4.0]undec-7-ene, 1,4-diazabicyclo[2.2.2]octane, or a tetra$C_{1-6}$alkylammonium hydroxide.

16. (Previously Presented) The process according to claim 1 wherein the base is triethylamine or a tetra$C_{1-6}$alkylammonium hydroxide.

17. (Previously Presented) The process according to claim 1 wherein the base is triethylamine.

18. (Previously Presented) The process according to claim 1 wherein between 3.2 and 3.8 mole equivalents of base is used based on the compound of formula (II), and wherein the compound of formula (III) is in the form of the dimethanesulfonate salt, the hydrochloride salt, the trifluoroacetate salt, or the sulfate salt.

19. (Previously Presented) The process according to claim 1 wherein X is chloro.

20. (Previously Presented) The process according to claim 1 wherein the compound of formula (III) is 4-aminomethyl-3-methoxyiminopyrrolidinium dimethanesulfonate.

21. (Previously Presented) The process according to claim 1 wherein R is $C_1$ alkyl.

22. (Previously Presented) The process according to claim 1 wherein the compound of formula (I) is (R,S)-7-(3-aminomethyl-4-*syn*-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate or a hydrate thereof.

23. (Currently Amended) A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt and/or hydrate thereof:



(I)

wherein R is $C_{1-4}$ alkyl or $C_{1-4}$ haloalkyl, which comprises reaction of a compound of formula (II):



(II)

wherein X is a leaving group; with a compound of formula (III):



(III)

wherein R is as defined for formula (I), or a salt thereof;

in the presence of a base and an aqueous solvent; wherein the base is ~~triethylamine, diisopropylamne, or~~ a tetra$C_{1-6}$alkylammonium hydroxide;

and optionally forming a pharmaceutically acceptable salt and/or hydrate thereof.

24-25. (Cancelled)

26. (Previously Presented) The process according to claim 23 wherein the base is tetrabutylammonium hydroxide or tetramethylammonium hydroxide.

27. (Previously Presented) The process according to claim 23 wherein the solvent is aqueous acetonitrile, an aqueous alcohol or water.

28. (Currently Amended) The process according to claim 23 wherein the solvent is aqueous acetonitrile and a ratio of between 0.7 and 1.4 acetontrile:water is used.

29. (Previously Presented) The process according to claim 23 wherein the compound of formula (III) is 4-aminomethyl-3-methoxyiminopyrrolidinium dimethanesulfonate.

30. (Previously Presented) The process according to claim 23 wherein R is $C_1$ alkyl.

31. (Previously Presented) The process according to claim 23 wherein the compound of formula (I) is (R,S)-7-(3-aminomethyl-4-*syn*-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate or a hydrate thereof.